Safety of topical OLEOZON® in the treatment of tinea pedis: Phase IV clinical trial

International Journal of Ozone Therapy

Volumn 7, Issue 1, 2008, Pages 55-59

  Menéndez, Silvia ^a,f   Re, L ^b   Falcon L ^c   Argote, M B ^c   Mendez I ^a   Fernandez D ^d   Elias Calle B ^e   Valero, M ^d  

^a Ozone Research Center Havana   (Cuba)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c HOSPITAL MILITAR CENTRAL DR CARLOS J FINLAY   (Cuba)

^d FINE   (Cuba)

^e Hospital General Dr Agostinho Neto   (Cuba)

^f NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Adverse drug reactions; Oleozon ; Ozonized vegetable oils; Phase IV clinical trial; Safety; Tinea pedis

Indexed keywords

OLEAZON; OZONE; SUNFLOWER OIL;

ADOLESCENT; ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; DEVELOPING COUNTRY; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ERYTHEMA; FEMALE; FUNGUS IDENTIFICATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OZONATION; PHASE 4 CLINICAL TRIAL; PRURITUS; SKIN BURNING SENSATION; TINEA PEDIS; TREATMENT DURATION;

EID: 43549123282     PISSN: 19723539     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Fauci AS, Braunwald E, Isselbacher KJ et Al: Principles of Internal Medicine. 14th, Edition. McGraw-Hill Companies Inc 1: 301-302, 1998.
2. Brooks KE, Bender JF: Tinea pedis: diagnosis and treatment. Clin Pediatr Med Surg 13: 31-46, 1996.
3. Lester M: Ketoconazole 2 percent cream in the treatment of tinea pedis, tinea cruris and tinea corporis. Cutis 55: 181-183, 1995.
4. Menéndez S, Falcón L, Simón DR et Al: Ozonized sunflower oil in the treatment of tinea pedis. Mycoses 45: 329-32, 2002.
5. Menéndez S, Fernández M, Amoroto M et Al: Eficacia y seguridad del OLEOZON® tópico en, el tratamiento de pacientes con impétigo. Rev Panam Infectol 9: 23-29, 2007.
6. Amoroto M, Fernández M, González ME et Al: Eficacia del aceite ozonizado (OLEOZON®) en el tratamiento de la giardiasis. Ensayo clínico fase III, aleatorizado, abierto y controlado. Rev Cubana de Farmacia 36: 173-175, 2002.
7. Vigna I, Menéndez S: Eficacia de la ozonoterapia en gatos con diferentes enfermedades oftalmológicas. RECVET 11: 11, 2007. http://www.veterinaria.org/revistas/recvet/n111107.html.
8. Sechi LA, Lezcano I, Nuñez N et Al: Antibacterial activity of ozonized sunflower oil (OLEOZON®), J Appl Microbiology 90: 279-284, 2001.
9. Lezcano I, Núñez N, Espino, M et Al: Antibacterial activity of ozonized sunflower oil, Oleozon®, against Staphylococcus aureus and Staphylococcus epidermidis. Ozone Sci & Eng 22: 207-214, 2000.
10. Lezcano I, Molerio J, Gómez M et Al: Actividad in vitro del OLEOZON® frente a agentes etiológicos de infecciones de la piel. Revista CENIC Ciencias Biológicas 29: 209-212, 1998.
11. Acevedo F, González J, Moleiro J et Al: Ensayo de toxicidad dérmica de 120 días del aceite ozonizado, OLEOZON®, en ratas Cenp. SPRD. Avances en Biotecnología Moderna 4: T4-T10, 1997.
12. Arteaga ME, Molerio J, Bada A et Al: Clasificación toxicológica del OLEOZON®, Revista CENIC Ciencias Biológicas 32: 57-9, 2001.
13. Llerena C, García G, Molerio J et Al: Irritabilidad dérmica del Oleozon®. Revista CENIC Ciencias Biológicas 26: 104-9, 1995.
14. Saple DG, Amar AK, Ravichandran G et Al: Efficacy and safety of butenafine in superficial dermatophytoses (tinea pedis, tinea cruris, tinea corporis). J Indian Med Assoc 99: 274-5, 2001.
15. Lebwohl M, Elewski B, Eisen D et Al: Efficacy and safety of terbinafine 1% solution in the treatment of interdigital tinea pedis and tinea corporis or tinea cruris. Cutis 67: 261-6, 2001.
16. Svejgaard E, Avnstorp C, Wanscher B et Al: Efficacy and safety of short-term itraconazole in tinea pedis: a double-blind, randomized, placebo-controlled trial. Dermatolog 197: 368-72, 1998.
17. Díaz M, Lezcano I, Molerio J et Al: Spectroscopic characterization of ozonides with biological activity. Ozone Sci & Eng: 35-40, 2001.
18. Ledea O, Correa T, Molerio J et Al: Volatile Components of Ozonized Sunflower Oil (OLEOZON®). Ozone Sci & Eng 23: 121-6, 2001.
19. Naranjo CA, Shear NH, Busto U: Adverse drug reaction. In: Kalant H. & Roschlau W H. E. (ods) Principles Medical Pharmacology, 6th ed. New York: Oxford University Press 1998: 791-800.
20. Falcón L, Menéndez S, Simón R et Al: Aceite ozonizado en dermatología. Experiencia de 9 años. Revista. CENIC Ciencias Biológicas 29: 165-8, 1998.
21. Martínez G, Merino N, Sam S et Al: Efecto histológico y bioquímico del OLEOZON® en el modelo de la cola de ratón. Revista CENIC Ciencias Biológicas 28: 31-4, 1997.
22. Tamoto K, Yamazaki A, Nochi H et Al: Ozononides of olive oil and methyl oleate inhibit the expression of cyclooxygenase-2 through the suppression of IκB/NFκB-dependent pathway in lipopolysaccharide-stimulate macrophage-like THP-1 cells. In: Proceedings of the 17th World Ozone Congress. Ozone in Medicine. Strasbourg, France: International Ozone Association 3: 1-5, 2005.